Severe Asthma


The progress in pharmacology and therapeutic exploration of free fatty acid receptors (FFARs) has significantly advanced from the initial stages of Graeme Milligan's pioneering research in this field. Subsequent insights resulted in Graeme and Andrew Tobin identifying the therapeutic potential of FFA4 activators to treat inflammatory airway diseases. The programme at Keltic will continue to progress the potential of FFA4 as a therapeutic target for chronic asthma.

Learn more about Keltic Pharma Therapeutics

We are happy to an answer questions about our company, malaria, drug discovery platform technology and partnering opportunities.